Eisai’s Severe Sepsis Drug Fails in Final-Stage Study
This article is for subscribers only.
Eisai Co. said its experimental drug to treat severe sepsis failed to save more lives than a placebo in a final-stage study.
The company won’t seek regulatory approval for eritoran in the U.S., Europe and Japan by March 31 as previously planned, Tokyo-based Eisai said in a statement today. Eisai said it will continue analyzing the trial data and determine its next course of action.